Glasgow prognostic score can be a prognostic indicator after percutaneous coronary intervention: a two-center study in Japan
Autor: | Ryota Noike, Shunsuke Matsuno, Hideo Amano, Takayuki Otsuka, Hiroto Kano, Junji Yajima, Hiroaki Semba, Shingo Matsumoto, Rine Nakanishi, Minoru Matsuhama, Takanori Ikeda, Ryo Okubo, Naoharu Yagi, Hiroto Aikawa, Yuji Oikawa, Yuko Kato, Takayuki Yabe, Takuto Arita, Mikio Kishi, Shinya Suzuki, Mitsuru Iida, Takeshi Yamashita, Shojiro Hirano, Yoshimasa Kojima, Tokuhisa Uejima, Yosuke Oka |
---|---|
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
medicine.medical_treatment Gastroenterology chemistry.chemical_compound Percutaneous Coronary Intervention Japan Internal medicine medicine Humans Myocardial infarction Renal Insufficiency Chronic Retrospective Studies Heart Failure Creatinine business.industry Percutaneous coronary intervention Prognosis medicine.disease Brain natriuretic peptide chemistry Heart failure Conventional PCI Hemodialysis Cardiology and Cardiovascular Medicine business Kidney disease |
Zdroj: | Heart and Vessels. 37:903-910 |
ISSN: | 1615-2573 0910-8327 |
Popis: | Glasgow prognostic score (GPS) has been used to evaluate inflammatory response and nutritional status. This study aimed to investigate the impact of nutritional status on cardiac prognosis by using GPS in patients after undergoing percutaneous coronary intervention (PCI). We included 862 patients who underwent PCI for stable angina pectoris between 2015 and 2018. We used the original cutoff values, which were an albumin (Alb) level of 3.5 g/dl and a C-reactive protein (CRP) level of 0.3 mg/dl. We categorized them into the three groups: originally defined GPS (od-GPS) 0 (high Alb and low CRP), 1 (low Alb or high CRP), and 2 (low Alb and high CRP). Major adverse clinical events (MACEs) included all-cause death, nonfatal myocardial infarction, revascularization, and hospitalization for heart failure. The median follow-up period was 398.5 days. During the follow-up, MACEs occurred in 136 patients. Od-GPS 2 had higher prevalence rates in terms of chronic kidney disease (CKD; 31.7% [229/722] vs. 44.9% [53/118] vs. 63.6% [14/22], p |
Databáze: | OpenAIRE |
Externí odkaz: |